Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Shida-Kawazoe M"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł :
Novel myostatin-specific antibody enhances muscle strength in muscle disease models.
Autorzy :
Muramatsu H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Kuramochi T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
Katada H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ueyama A; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ruike Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ohmine K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Miyano-Nishizawa R; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Shimizu Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Okuda M; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Hayashi M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Haraya K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ban N; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Nonaka T; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Honda M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Kitamura H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Igawa T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Nezu J; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 Jan 25; Vol. 11 (1), pp. 2160. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Autorzy :
Kamata-Sakurai M; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan. .
Narita Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Nemoto T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Uchikawa R; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Honda M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Hironiwa N; Chugai Pharmabody Research Pte. Ltd., Synapse, Singapore.
Taniguchi K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Metsugi S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Miyazaki T; Clinical Development Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Wada NA; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Ohte Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Shimizu S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Mikami H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Ono N; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Adachi K; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Sakiyama T; Pharmaceutical Technology Division, Chugai Pharmaceutical Co., Ltd., Kita-ku, Tokyo, Japan.
Matsushita T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Kadono S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Komatsu SI; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Sakamoto A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Horikawa S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Hirako A; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Hamada K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Naoi S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Savory N; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Satoh Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Sato M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Noguchi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Shinozuka J; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Kuroi H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Ito A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Wakabayashi T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Kamimura M; Chugai Research Institute for Medical Science, Inc., Kamakura, Kanagawa, Japan.
Isomura F; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan.
Tomii Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Sawada N; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Kato A; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Ueda O; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Nakanishi Y; Project & Lifecycle Management Unit, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan.
Endo M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Jishage KI; Chugai Research Institute for Medical Science, Inc., Kamakura, Kanagawa, Japan.; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan.
Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Igawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.; Chugai Pharmabody Research Pte. Ltd., Synapse, Singapore.
Pokaż więcej
Źródło :
Cancer discovery [Cancer Discov] 2020 Aug 25. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
Autorzy :
Sampei Z; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Haraya K; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Fukuzawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Gan SW; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Shimizu Y; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Ruike Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Feng S; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Kuramochi T; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Muraoka M; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Igawa T; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Nezu J; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2018 Dec 28; Vol. 13 (12), pp. e0209509. Date of Electronic Publication: 2018 Dec 28 (Print Publication: 2018).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*genetics
Complement Activation/*drug effects
Complement C5/*antagonists & inhibitors
Protein Engineering/*methods
Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antibody Affinity ; Complement Activation/immunology ; Complement C5/immunology ; Complement C5/isolation & purification ; Computer Simulation ; Drug Discovery/methods ; Endosomes/immunology ; Histocompatibility Antigens Class I/genetics ; Histocompatibility Antigens Class I/immunology ; Humans ; Hydrogen-Ion Concentration ; Immune System Diseases/drug therapy ; Immune System Diseases/immunology ; Macaca fascicularis ; Mice ; Mice, Transgenic ; Mutagenesis ; Receptors, Fc/genetics ; Receptors, Fc/immunology ; Recombinant Proteins/immunology ; Recombinant Proteins/isolation & purification ; Time Factors
Czasopismo naukowe
Tytuł :
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.
Autorzy :
Fukuzawa T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Sampei Z; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Haraya K; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Ruike Y; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Shimizu Y; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Gan SW; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Irie M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Tsuboi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Tai H; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan.
Sakiyama T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Sakamoto A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Ishii S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Maeda A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Iwayanagi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Shibahara N; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Shibuya M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Nakamura G; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Nambu T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Hayasaka A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Mimoto F; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Okura Y; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Habu K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Wada M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Miura T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Honda K; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
Tsunoda H; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Igawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Nezu J; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2017 Apr 24; Vol. 7 (1), pp. 1080. Date of Electronic Publication: 2017 Apr 24.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Neutralizing/*immunology
Complement C5/*antagonists & inhibitors
Complement C5/*immunology
Animals ; Antibodies, Neutralizing/administration & dosage ; Antibodies, Neutralizing/chemistry ; Complement C5/chemistry ; Crystallography, X-Ray ; Hemoglobinuria, Paroxysmal/drug therapy ; Humans ; Macaca fascicularis ; Protein Binding ; Protein Conformation
Czasopismo naukowe
Tytuł :
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Autorzy :
Mimoto F; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Igawa T
Kuramochi T
Katada H
Kadono S
Kamikawa T
Shida-Kawazoe M
Hattori K
Pokaż więcej
Źródło :
MAbs [MAbs] 2013 Mar-Apr; Vol. 5 (2), pp. 229-36. Date of Electronic Publication: 2013 Feb 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibody Affinity*
Antibody Specificity*
Antibodies, Monoclonal/*genetics
Immunoglobulin Fc Fragments/*genetics
Protein Engineering/*methods
Receptors, IgG/*metabolism
Amino Acid Substitution ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/metabolism ; Antibody-Dependent Cell Cytotoxicity ; Cell Line ; Fucose/metabolism ; Genetic Variation ; Humans ; Immunoglobulin Fc Fragments/chemistry ; Immunoglobulin Fc Fragments/metabolism ; Protein Binding
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies